These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 27186941

  • 1. Morbidities in non-transfusion-dependent thalassemia.
    Saliba AN, Taher AT.
    Ann N Y Acad Sci; 2016 Mar; 1368(1):82-94. PubMed ID: 27186941
    [Abstract] [Full Text] [Related]

  • 2. Non-Transfusion-Dependent Thalassemia: An Update on Complications and Management.
    Sleiman J, Tarhini A, Bou-Fakhredin R, Saliba AN, Cappellini MD, Taher AT.
    Int J Mol Sci; 2018 Jan 08; 19(1):. PubMed ID: 29316681
    [Abstract] [Full Text] [Related]

  • 3. Non-Transfusion-Dependent Thalassemia: A Panoramic Review.
    Shash H.
    Medicina (Kaunas); 2022 Oct 21; 58(10):. PubMed ID: 36295656
    [Abstract] [Full Text] [Related]

  • 4. New therapeutic targets in transfusion-dependent and -independent thalassemia.
    Cappellini MD, Motta I.
    Hematology Am Soc Hematol Educ Program; 2017 Dec 08; 2017(1):278-283. PubMed ID: 29222267
    [Abstract] [Full Text] [Related]

  • 5. Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia.
    Taher AT, Temraz S, Cappellini MD.
    Expert Rev Hematol; 2013 Oct 08; 6(5):495-509. PubMed ID: 24083402
    [Abstract] [Full Text] [Related]

  • 6. Iron overload in non-transfusion-dependent thalassemia: a clinical perspective.
    Musallam KM, Cappellini MD, Wood JC, Taher AT.
    Blood Rev; 2012 Apr 08; 26 Suppl 1():S16-9. PubMed ID: 22631036
    [Abstract] [Full Text] [Related]

  • 7. Iron overload in thalassemia: different organs at different rates.
    Taher AT, Saliba AN.
    Hematology Am Soc Hematol Educ Program; 2017 Dec 08; 2017(1):265-271. PubMed ID: 29222265
    [Abstract] [Full Text] [Related]

  • 8. Novel approach to reactive oxygen species in nontransfusion-dependent thalassemia.
    Tyan PI, Radwan AH, Eid A, Haddad AG, Wehbe D, Taher AT.
    Biomed Res Int; 2014 Dec 08; 2014():350432. PubMed ID: 25121095
    [Abstract] [Full Text] [Related]

  • 9. Increasing prevalence of thalassemia in America: Implications for primary care.
    Sayani FA, Kwiatkowski JL.
    Ann Med; 2015 Dec 08; 47(7):592-604. PubMed ID: 26541064
    [Abstract] [Full Text] [Related]

  • 10. Treating iron overload in patients with non-transfusion-dependent thalassemia.
    Taher AT, Viprakasit V, Musallam KM, Cappellini MD.
    Am J Hematol; 2013 May 08; 88(5):409-15. PubMed ID: 23475638
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Management of non-transfusion-dependent thalassemia: a practical guide.
    Taher AT, Cappellini MD.
    Drugs; 2014 Oct 08; 74(15):1719-29. PubMed ID: 25255924
    [Abstract] [Full Text] [Related]

  • 13. [Current management of thalassemia intermedia].
    Thuret I.
    Transfus Clin Biol; 2014 Nov 08; 21(4-5):143-9. PubMed ID: 25282488
    [Abstract] [Full Text] [Related]

  • 14. How I treat non-transfusion-dependent β-thalassemia.
    Saliba AN, Musallam KM, Taher AT.
    Blood; 2023 Sep 14; 142(11):949-960. PubMed ID: 37478396
    [Abstract] [Full Text] [Related]

  • 15. Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions.
    Porter JB, Cappellini MD, Kattamis A, Viprakasit V, Musallam KM, Zhu Z, Taher AT.
    Br J Haematol; 2017 Jan 14; 176(2):288-299. PubMed ID: 27917462
    [Abstract] [Full Text] [Related]

  • 16. Pulmonary hypertension in non-transfusion-dependent thalassemia: Correlation with clinical parameters, liver iron concentration, and non-transferrin-bound iron.
    Inthawong K, Charoenkwan P, Silvilairat S, Tantiworawit A, Phrommintikul A, Choeyprasert W, Natesirinilkul R, Siwasomboon C, Visrutaratna P, Srichairatanakool S, Chattipakorn N, Sanguansermsri T.
    Hematology; 2015 Dec 14; 20(10):610-7. PubMed ID: 25964094
    [Abstract] [Full Text] [Related]

  • 17. Interaction of Transfusion and Iron Chelation in Thalassemias.
    Porter JB, Garbowski MW.
    Hematol Oncol Clin North Am; 2018 Apr 14; 32(2):247-259. PubMed ID: 29458730
    [Abstract] [Full Text] [Related]

  • 18. Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia.
    Bou-Fakhredin R, Bazarbachi AH, Chaya B, Sleiman J, Cappellini MD, Taher AT.
    Int J Mol Sci; 2017 Dec 20; 18(12):. PubMed ID: 29261151
    [Abstract] [Full Text] [Related]

  • 19. Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes.
    Ricchi P, Marsella M.
    Drug Des Devel Ther; 2015 Dec 20; 9():6475-82. PubMed ID: 26719673
    [Abstract] [Full Text] [Related]

  • 20. Review of disease-related complications and management in adult patients with thalassemia: A multi-center study in Thailand.
    Chuncharunee S, Teawtrakul N, Siritanaratkul N, Chueamuangphan N.
    PLoS One; 2019 Dec 20; 14(3):e0214148. PubMed ID: 30893381
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.